Loading...

Εκπαιδευτικά προγράμματα

Καταχωρήθηκε: Τρίτη 27 Απρ 2021
Excellent case based report on npm1 Mut Aml  Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τρίτη 27 Απρ 2021
Comprehensive review for AML treatment. New directions applied in MD Anderson CC Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Δευτέρα 12 Απρ 2021
New guidelines for treatment of MM (EHA/ESMO) Presenter S. Kastritis Participation Spyridonidis, Liga, Tsokanas Diagnostic obligatory are still Free light chain serum, 24-Urin, cytogenetics (Del17p, t(4,14), WBLD-CT and if  negative Whole body MRI. Asymptomatic MM (use 20/2/20 score), if high (2 of 3) risk score these pats...
Καταχωρήθηκε: Τρίτη 30 Μάρ 2021
https://www.ebmt.org/sites/default/files/2021-02/EBMT%20COVID-19%20guidelines%20v.%2015.02%202021-02-18.pdf Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τετάρτη 24 Μάρ 2021
Ebmt proposes to vaccinate after day 100 https://www.ecdc.europa.eu/en/publications-data/coronavirus-disease-2019-covid-19-and-supply-substances-human-origin Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Δευτέρα 22 Μάρ 2021
An important paper published in Blood showed that prophylaxis is not  always wihtout harm. Pts under letermovir prophylaxis may be at risk for  late CMV infection after HCT because of delay CMV-specific cellular  reconstitution (which is due to the letermovir induced decreased CMV  antigen exposure). JOURNAL ARTICLE Cytomegalovirus-specific T-cell Reconstitution...
Καταχωρήθηκε: Δευτέρα 08 Μάρ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τρίτη 23 Φεβ 2021
New England Journal of Medicine. 2020 Dec 24; 383 (26) : 2526-2537. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. Andrew H Wei, Hartmut Döhner, Christopher Pocock, Pau Montesinos, Boris Afanasyev, Hervé Dombret, Farhad Ravandi, Hamid Sayar, Jun-Ho Jang, Kimmo Porkka, Dominik Selleslag,...
Καταχωρήθηκε: Τρίτη 16 Φεβ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τρίτη 09 Φεβ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τρίτη 02 Φεβ 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Δευτέρα 01 Φεβ 2021
https://register.gotowebinar.com/register/6711366611927088656 Stem Cell Transplantation - a Post ASH 2020 Summary Tuesday, February 2, 2021 Professor Arnon Nagler, MD, MSc Participants: Prof.Spyridonidis, Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Τετάρτη 20 Ιαν 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Πέμπτη 14 Ιαν 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Παρασκευή 08 Ιαν 2021
Duration of shedding of viable SARS-CoV-2 in severely immunosuppressed  patients with cancer For most patients with COVID-19, persistently positive nucleic acid  testing after symptom resolution does not indicate prolonged  infectiousness. However, accumulating evidence suggests that some  severely immunocompromised patients may have prolonged shedding of  viable SARS-CoV-2. One study of 20 patients with...
Καταχωρήθηκε: Δευτέρα 04 Ιαν 2021
Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Δευτέρα 21 Δεκ 2020
Study showing the different significance of allelia or Niall epic  tp53 mutation in AML as recently showed in MDS Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka
Καταχωρήθηκε: Πέμπτη 10 Δεκ 2020
We discussed the use of Tki after allo hct for ph + ALL and our current practice. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas, Dr Lekka, Dr Kostopoulou Leukemia. 2020 Nov 17; A new pre-emptive TKIs strategy for preventing relapse based on BCR/ABL monitoring for Ph+ALL undergoing allo-HCT:...
Καταχωρήθηκε: Τετάρτη 02 Δεκ 2020
In this large, prospective cohort of fit older adults with advanced MDS, we found that survival was significantly improved if HCT was performed early or for adverse risk disease but not for standard risk disease with severe cytopenia. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Tsokanas,...
Καταχωρήθηκε: Τετάρτη 18 Νοέ 2020
A must read review. Presenter: Prof.Spyridonidis Participants: Dr Liga, Dr Lekka, Dr Kostopoulou
Βρέθηκαν 281 αποτελέσματα. Σελίδα 1 από 15
Σελίδα [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] > >>
 

 

Τηλέφωνα Επικοινωνίας:

 

Γραμματεία MMMO: 2613 603506 (ασθενείς), 2613 604062 (Γραμματεία Διευθυντή) 
Fax : 2613 604066,
email (για ιατρούς): transplant@upatras.gr,
email (για ασθενείς): mmak@upatras.gr
email (για θέματα κλινικών μελετών) : gcppatras@gmail.com
Μονάδα Μεταμόσχευσης (Νοσηλεία): 2613 603 261
Γραφείο Ιατρών: 2613 604064, 2613 604065,
Εφημερεύων Ιατρός: 2610 999111 (τηλ. κέντρο ΠΓΝΠ)

 

βρείτε μας στο χάρτη

 

Login / Sitemap

 

© Copyright 2015 - 2021 Μονάδα Μεταμόσχευσης Μυελού των Οστών Πάτρας